论文部分内容阅读
背景化学疗法中,药物或者药物组合的最佳剂量通常都是通过随机对照临床试验确定的。对于成年癌症患者,药物使用剂量传统上都是基于该患者的估算体表面积(BSA)确定的。有确凿证据表明,从标准剂量中减量或者降低剂量强度会影响患者无病生存期(DFS)和总体存活率(OS)。此外,还有作者认为应该将癌症化学疗法的最佳实施作为评估治疗质量的指标。虽然无数研究已经证实,完全基于患者体重的细胞毒性化疗药物剂量[静脉给药(IV)及口服]的安全性和重要性,但许
In the context of chemotherapy, the optimal dose of a drug or drug combination is usually determined by randomized controlled clinical trials. For adult cancer patients, drug use doses have traditionally been determined based on the patient’s estimated body surface area (BSA). There is strong evidence that decreasing or decreasing dose intensity from the standard dose affects patient disease-free survival (DFS) and overall survival (OS). In addition, there are authors who believe that the best implementation of cancer chemotherapy should be used as an indicator to assess the quality of treatment. Although numerous studies have confirmed the safety and importance of cytotoxic chemotherapeutic drug dosages (intravenous (IV) and oral) based solely on the patient’s weight,